{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:26:49Z","timestamp":1793683609981,"version":"4.5.1"},"reference-count":123,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.clml.2014.03.006","type":"journal-article","created":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T14:46:00Z","timestamp":1402497960000},"page":"1-12.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Efficacy and Safety in Relapsed\/Refractory Mantle Cell Lymphoma: A Systematic Literature Review"],"prefix":"10.1016","volume":"15","author":[{"given":"Annete","family":"Njue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Colosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Trask","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Olivares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Abbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Police","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Ruiz-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.03.006_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.critrevonc.2011.05.001","article-title":"Mantle cell lymphoma","volume":"82","author":"Cortelazzo","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2014.03.006_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.12046","article-title":"Guidelines for the investigation and management of mantle cell lymphoma","volume":"159","author":"McKay","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1053\/j.seminhematol.2011.05.001","article-title":"Molecular targeted approaches in mantle cell lymphoma","volume":"48","author":"Weniger","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2014.03.006_bib4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07124.x","article-title":"Advances in the understanding of mantle cell lymphoma","volume":"142","author":"Jares","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/CCO.0b013e328363df0b","article-title":"The current therapeutic scenario for relapsed mantle cell lymphoma","volume":"25","author":"Ferrero","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.22093","volume":"107","author":"Nickenig","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.03.006_bib8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/asheducation-2009.1.542","article-title":"Current treatment standards and emerging strategies in mantle cell lymphoma","author":"Dreyling","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2014.03.006_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2141.2005.05777.x","article-title":"Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma","volume":"131","author":"Bauwens","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib11","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib12","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3109\/10428194.2011.575489","article-title":"Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma","volume":"52","author":"Spurgeon","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.03.006_bib13","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.03.006_bib14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00277-006-0193-2","article-title":"The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma","volume":"86","author":"Ritchie","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2014.03.006_bib16","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Ghielmini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.03.006_bib17","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib18","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2014.03.006_bib19","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A\u00a0revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.03.006_bib20","unstructured":"National Institute for Health and Clinical Excellence. Single Technology Appraisal (STA). Specification for manufacturer\/sponsor submission of evidence. October 2009. Available at: http:\/\/www.nice.org.uk\/media\/D6D\/E2\/SpecificationForManufacturerSponsorSubmissionEvidence.doc. Accessed November 5,\u00a02013."},{"key":"10.1016\/j.clml.2014.03.006_bib21","unstructured":"Centre for Reviews and Dissemination. Systematic Reviews. CRD's Guidance for Undertaking Reviews in Health Care. University of York; January 2009. Available at: http:\/\/www.york.ac.uk\/inst\/crd\/pdf\/Systematic_Reviews.pdf. Accessed November 5,\u00a02013."},{"key":"10.1016\/j.clml.2014.03.006_bib22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.4884.4884","article-title":"Durable responses with bendamustine monotherapy in patients with relapsed\/refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) and mantle-cell lymphoma (MCL): updated follow-up data from a Japanese multicenter phase II study","volume":"116","author":"Itoh","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.03.006_bib23","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib24","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/j.1349-7006.2010.01635.x","article-title":"Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"101","author":"Ohmachi","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2014.03.006_bib25","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib26","unstructured":"ClinicalTrials.gov [Web site]. Study Evaluating Temsirolimus (CCI-779) in Mantle Cell Lymphoma (MCL) (OPTIMAL). Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00117598?term=NCT00117598&rank=1. Accessed: November 7,\u00a02013."},{"key":"10.1016\/j.clml.2014.03.006_bib27","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib28","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.03.006_bib29","unstructured":"Rule A, Furtado M, Eve H, et\u00a0al. The addition of bortezomib to standard dose CHOP chemotherapy significantly improves survival in relapsed mantle cell lymphoma. Presented at the 17th Congress of the European Hematology Association; June 14-17, 2012, Helsinki, Finland."},{"key":"10.1016\/j.clml.2014.03.006_bib30","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.3655.3655","article-title":"Encouraging activity of obinutuzumab (GA101) monotherapy in relapsed\/refractory aggressive non-Hodgkin lymphoma: results from a phase II study (BO20999)","volume":"118","author":"Morschhauser","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.03.006_bib31","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/cncr.22196","article-title":"Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma","volume":"107","author":"Robak","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.03.006_bib32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2010.08340.x","article-title":"Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia","volume":"151","author":"Agathocleous","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/10428199709114170","article-title":"Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin lymphoma","volume":"25","author":"Liliemark","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.03.006_bib34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1532\/IJH97.04077","article-title":"Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study","volume":"80","author":"Ogura","year":"2004","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2014.03.006_bib35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JCO.2005.03.9313","article-title":"Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma","volume":"24","author":"Tobinai","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/hon.891","article-title":"A\u00a0multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36\/03","volume":"27","author":"Hitz","year":"2009","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib37","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0959-8049(02)00143-0","article-title":"Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin lymphoma","volume":"38","author":"Rummel","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2014.03.006_bib38","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00277-004-0858-7","article-title":"High incidence of complications\u00a0after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients\u00a0with advanced lymphoproliferative malignancies","volume":"83","author":"Van Den Neste","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2014.03.006_bib39","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/annonc\/mdm133","article-title":"Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy","volume":"18","author":"El Gnaoui","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib40","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A\u00a0phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"14","author":"Rizzieri","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.03.006_bib41","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2008.07353.x","article-title":"Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma","volume":"143","author":"Pro","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib42","first-page":"513","article-title":"131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital","volume":"18","author":"Turner","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.clml.2014.03.006_bib43","first-page":"400","article-title":"Therapy with 90Y ibritumomab tiuxetan in relapsed\/refractory non-Hodgkin lymphoma. Analysis of recent outcomes (abstract 0962)","volume":"96","author":"Giraldo","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.03.006_bib44","first-page":"888","article-title":"Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin lymphomas","volume":"88","author":"Borchmann","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.03.006_bib45","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cncr.21219","article-title":"Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma","volume":"104","author":"Oki","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.03.006_bib46","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2011-02-334904","article-title":"Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas","volume":"118","author":"Witzig","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.03.006_bib47","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib48","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","article-title":"High anti-lymphoma activity of bendamustine\/mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"48","author":"Weide","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.03.006_bib49","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib50","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A\u00a0phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150","volume":"18","author":"Belch","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib52","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/cncr.25792","article-title":"Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma","volume":"117","author":"Baiocchi","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.03.006_bib53","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","article-title":"Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma","volume":"96","author":"Lamm","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.03.006_bib54","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.2001.02795.x","article-title":"Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin lymphoma","volume":"113","author":"Dumontet","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib55","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdl395","article-title":"Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma","volume":"18","author":"Morschhauser","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib56","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10637-008-9191-7","article-title":"Results of a phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma","volume":"27","author":"Garbo","year":"2009","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2014.03.006_bib57","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1080\/10428190701618268","article-title":"Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma","volume":"48","author":"Rodriguez","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.03.006_bib58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A\u00a0phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.03.006_bib59","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib60","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib61","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2141.2008.07271.x","article-title":"A\u00a0multicentre phase II clinical experience with the novel aza-epothilone ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma","volume":"143","author":"O'Connor","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib62","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1080\/10428190902856808","article-title":"A\u00a0phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group study S0108","volume":"50","author":"Stopeck","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.03.006_bib63","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00280-009-1185-4","article-title":"Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed\/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial","volume":"65","author":"Rolland","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2014.03.006_bib64","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/10428190290016908","article-title":"Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma","volume":"43","author":"Lin","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.03.006_bib65","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in\u00a0vitro sensitivity and tumor necrosis factor alpha response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib66","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/10428194.2010.546015","article-title":"A\u00a0phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)","volume":"52","author":"Kouroukis","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.03.006_bib67","unstructured":"Chiappellam A, Pregnom P, Zinzanim PL, et\u00a0al. Weekly infusion of rituximab and bortezomib is effective and safe in relapsed\/refractory indolent and mantle cell lymphoma: long term analysis of a phase II trial of Italian Lymphoma Foundation (FIL) (abstract 0381). Presented at the 16th Congress of the European Hematology Association, London, UK, June 9-12,\u00a02011."},{"key":"10.1016\/j.clml.2014.03.006_bib68","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2825.2825","article-title":"Rituximab plus gemcitabine and oxaliplatin as salvage therapy in patients with relapsed\/refractory mantle-cell lymphoma","volume":"116","author":"Gironella","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.03.006_bib69","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.3963.3963","article-title":"PILLAR-1: preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib","volume":"116","author":"O'Connor","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.03.006_bib70","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.03.006_bib71","article-title":"The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously treated mantle cell lymphoma (MCL): preliminary results of a phase II trial","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.03.006_bib72","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib73","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2141.2008.07466.x","volume":"145","author":"O'Connor","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib74","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","article-title":"A\u00a0multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.03.006_bib75","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib76","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3324\/haematol.2011.051813","article-title":"Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers","volume":"97","author":"Zaja","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.03.006_bib77","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib78","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/cncr.23880","article-title":"Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma","volume":"113","author":"Wang","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.03.006_bib79","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","article-title":"Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma","volume":"27","author":"Wang","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib80","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib81","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib82","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1794.1794","article-title":"Efficacy and safety of thalidomide in mantle cell\u00a0lymphoma: results of the French ATU Program","volume":"116","author":"Harel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.03.006_bib83","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib84","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib85","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib86","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib87","unstructured":"Clark T. Data is King. May 2012. Available at: http:\/\/www.samedanltd.com\/pdfs\/art_13_173_3241_7464243.pdf. Accessed November 7,\u00a02013."},{"key":"10.1016\/j.clml.2014.03.006_bib88","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib89","series-title":"Imbruvica (ibrutinib) [prescribing information]","year":"2013"},{"key":"10.1016\/j.clml.2014.03.006_bib90","unstructured":"European Medicines Association (EMA). Public Summary of Opinion on Orphan Designation. Temsirolimus for the Treatment of Mantle Cell Lymphoma. EMA\/COMP\/195543\/2008 Rev.1. November 15, 2011. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2009\/10\/WC500005687.pdf. Accessed November 7,\u00a02013."},{"key":"10.1016\/j.clml.2014.03.006_bib91","series-title":"Torisel Summary of Product Characteristics","year":"2012"},{"key":"10.1016\/j.clml.2014.03.006_bib92","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.03.006_bib93","doi-asserted-by":"crossref","unstructured":"Goy A, Sinha R, Williams ME, et\u00a0al. Phase II multicenter study of single-agent lenalidomide in subjects with mantle cell lymphoma who relapsed or progressed after or were refractory to bortezomib: the MCL-001 \u201cEMERGE\u201d study (abstract 905). Presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition, Atlanta, GA, December 8-12,\u00a02012.","DOI":"10.1182\/blood.V120.21.905.905"},{"key":"10.1016\/j.clml.2014.03.006_bib94","unstructured":"U.S. Food and Drug Administration. Lenalidomide. Approval History. June 5, 2013. Available at: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed November 14,\u00a02013."},{"key":"10.1016\/j.clml.2014.03.006_bib97","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib98","unstructured":"ClinicalTrials.gov [Web site]. Study Evaluating Temsirolimus (CCI-779) in Mantle Cell Lymphoma (MCL) (OPTIMAL). Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00117598?term=NCT00117598&rank=1. Accessed: November 7,\u00a02013."},{"key":"10.1016\/j.clml.2014.03.006_bib99","unstructured":"Rule A, Furtado M, Eve H, et\u00a0al. The addition of bortezomib to standard dose CHOP chemotherapy significantly improves survival in relapsed mantle cell lymphoma. Presented at the 17th Congress of the European Hematology Association; June 14-17, 2012, Helsinki, Finland."},{"key":"10.1016\/j.clml.2014.03.006_bib100","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.03.006_bib101","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2010.08340.x","article-title":"Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia","volume":"151","author":"Agathocleous","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib102","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.3655.3655","article-title":"Encouraging activity of obinutuzumab (GA101) monotherapy in relapsed\/refractory aggressive non-Hodgkin lymphoma: results from a phase II study (BO20999)","volume":"118","author":"Morschhauser","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.03.006_bib103","first-page":"888","article-title":"Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin lymphomas","volume":"88","author":"Borchmann","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.03.006_bib104","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/j.1349-7006.2010.01635.x","article-title":"Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"101","author":"Ohmachi","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2014.03.006_bib105","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1532\/IJH97.04077","article-title":"Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study","volume":"80","author":"Ogura","year":"2004","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2014.03.006_bib106","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/10428199709114170","article-title":"Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin lymphoma","volume":"25","author":"Liliemark","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.03.006_bib107","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A\u00a0phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"14","author":"Rizzieri","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.03.006_bib108","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JCO.2005.03.9313","article-title":"Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma","volume":"24","author":"Tobinai","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib109","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.2001.02795.x","article-title":"Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin lymphoma","volume":"113","author":"Dumontet","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/hon.891","article-title":"A\u00a0multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36\/03","volume":"27","author":"Hitz","year":"2009","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib111","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2141.2008.07271.x","article-title":"A\u00a0multicentre phase II clinical experience with the novel aza-epothilone ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma","volume":"143","author":"O'Connor","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib112","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib113","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib114","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cncr.21219","article-title":"Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma","volume":"104","author":"Oki","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.03.006_bib115","first-page":"513","article-title":"131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital","volume":"18","author":"Turner","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.clml.2014.03.006_bib116","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib117","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/cncr.25792","article-title":"Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma","volume":"117","author":"Baiocchi","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.03.006_bib118","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2008.07353.x","article-title":"Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma","volume":"143","author":"Pro","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.03.006_bib119","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/cncr.22196","article-title":"Rituximab combined with cladribine or\u00a0with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma","volume":"107","author":"Robak","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.03.006_bib120","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdl395","article-title":"Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma","volume":"18","author":"Morschhauser","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib121","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00277-004-0858-7","article-title":"High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies","volume":"83","author":"Van Den Neste","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2014.03.006_bib122","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0959-8049(02)00143-0","article-title":"Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin lymphoma","volume":"38","author":"Rummel","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2014.03.006_bib123","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1080\/10428190701618268","article-title":"Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma","volume":"48","author":"Rodriguez","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.03.006_bib124","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/annonc\/mdm133","article-title":"Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy","volume":"18","author":"El Gnaoui","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.03.006_bib125","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.4884.4884","article-title":"Durable responses with bendamustine monotherapy in patients with relapsed\/refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) and mantle-cell lymphoma (MCL): updated follow-up data from a Japanese multicenter phase II study","volume":"116","author":"Itoh","year":"2010","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014001529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014001529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:35Z","timestamp":1761870335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014001529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S2152265014001529"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.03.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Efficacy and Safety in Relapsed\/Refractory Mantle Cell Lymphoma: A Systematic Literature Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}